Phase 3, Randomized, Safety, Lot Consistency and Clinical Benefit Study of Recombinant Botulinum Vaccine A/B

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE3

Study Classification

INTERVENTIONAL

Study Start Date

2017-10-31

Study Completion Date

2019-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This Phase 3 clinical trial is a double blind, placebo-controlled, randomized, multicenter investigation of rBV A/B in male and female healthy adults 18 to 55 years of age.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Double Blind, Safety and Immunogenicity Study of Recombinant Botulinum Vaccine A/B

NCT00764634

Botulism Vaccine

COMPLETED PHASE2

Study to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant Botulinum Vaccine A/B in Healthy Adults

NCT00098098

RECOMBINANT BOTULINUM VACCINE A/B

COMPLETED PHASE1

Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia

NCT00257660

Cervical Dystonia

COMPLETED PHASE3

Single or Repeat Dose of G03-52-01 in Adult Subjects

NCT05348993

Healthy Botulinum Toxin

COMPLETED PHASE2

Assessment of Effectiveness and Safety of Dysport® for the Treatment of Hemifacial Spasm

NCT00276315

Hemifacial Spasm

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Currently, there are no licensed vaccines or pre-exposure prophylactic medical countermeasures available to provide protection against botulism. The rBV A/B is under development to provide protection of adults 18 to 55 years of age from fatal botulism caused by inhalational intoxication with botulinum neurotoxin complex (BoNT) serotype A, subtype A1 (BoNT/A1) and botulinum neurotoxin complex serotype B, subtype B1 (BoNT/B1). Volunteers will not be exposed to botulism. Protective antibody titers will be measured in serum after vaccination.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Botulism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

rBV A/B

0.5 mL dose of rBV A/B (40 µg) will be administered intramuscularly (IM) in a three-dose dosing schedule given at Days 0, 28 ± 5 days, and 182 ± 9 days

Group Type ACTIVE_COMPARATOR

rBV A/B

Intervention Type BIOLOGICAL

0.5 mL dose of rBV A/B (40 µg) given at Days 0, 28 ± 5 days, and 182 ± 9 days

Placebo

0.5 mL dose of placebo will be administered intramuscularly (IM) given at Days 0, 28 ± 5 days, and 182 ± 9 days

Group Type PLACEBO_COMPARATOR

Placebo (USP sterile saline for injection)

Intervention Type BIOLOGICAL

0.5 mL dose of Placebo will be given at Days 0, 28 ± 5 days, and 182 ± 9 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

rBV A/B

0.5 mL dose of rBV A/B (40 µg) given at Days 0, 28 ± 5 days, and 182 ± 9 days

Intervention Type BIOLOGICAL

Placebo (USP sterile saline for injection)

0.5 mL dose of Placebo will be given at Days 0, 28 ± 5 days, and 182 ± 9 days

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The volunteer is a U.S. citizen or permanent resident alien of the U.S.
2. The volunteer has signed the informed consent form.
3. The volunteer is 18 to 55 years of age.
4. The volunteer agrees not to donate blood or blood product for therapeutic or research purposes.
5. The volunteer is willing to comply with the requirements of the protocol through the last scheduled visit.
6. The volunteer is accessible by telephone or electronic mail to receive reminders from the investigative site.
7. Female volunteers of childbearing potential must not be pregnant or lactating and agree to use two types of an acceptable form of FDA-approved contraception through end of study.
8. The volunteer is in good health.
9. The volunteer has clinical laboratory tests within acceptable ranges listed in the protocol.

Exclusion Criteria

1. The volunteer has a history of botulism or prior receipt of any botulinum vaccine, toxoid or antitoxin.
2. The volunteer has previously been treated or expects to be treated with any therapeutic products containing BoNTs such as Botox®, Myobloc®/Neurobloc™ and Botox® Cosmetic.
3. The volunteer has a history of hypersensitivity or significant adverse reaction to other vaccines, aluminum compounds or yeast.
4. The volunteer has a history of severe allergic reactions or anaphylaxis.
5. The volunteer has donated one or more units of blood (≥ 450 mL) or undergone plasmapheresis within the past 28 days prior to receiving first administration of study product.
6. The volunteer received any blood product or immunoglobulin in the previous 6 months prior to receiving first vaccination or plans to receive such products during the clinical trial.
7. The volunteer received any investigational vaccine in the previous 6 months.
8. The volunteer received or intends to receive any licensed nonliving vaccine within 14 days before or after a scheduled administration of study product.
9. The volunteer received or intends to receive any licensed live vaccine, including FluMist® within 60 days before or after a scheduled administration of study product.
10. Vaccination with commercially available inactivated or non-living influenza vaccine preparations (other than FluMist®) if received 14 days before and after a scheduled administration of study product.
11. The volunteer received any investigational drug therapy within 30 days before the first vaccination or before the last scheduled visit.
12. The volunteer received therapy with immunosuppressive agents, including use of moderate to high-dose oral inhaled or systemic corticosteroids (prednisone-equivalent dose of ≥ 20 mg/day).
13. The volunteer has or develops medically diagnosed chronic migraine headaches (persistent and recurrent) or a neurological condition associated with a cranial nerve or spasticity or abnormal muscle contraction, demyelination, other abnormalities of smooth or skeletal muscle function or hyperhidrosis.
14. The volunteer had systemic or recurrent disease or condition that would place the volunteer at an unacceptable risk of injury or requires frequent or continuous medical intervention for treatment, has required hospitalization, or is likely to require surgical intervention during the course of the study.
15. The volunteer has current active mental illness, history of mental illness or hospitalization for mental illness within the past 12 months prior to first of administration of study product is exclusionary.
16. The volunteer has a history of immunodeficiency or autoimmune disease.
17. The volunteer has a systemic medical condition that is ongoing or has required hospitalization or administration of antimicrobial agents within 6 months before screening.
18. The volunteer has a history of or active rheumatoid arthritis or any autoimmune mediated arthritis.
19. The volunteer has an acute self-limited illness that has not resolved by the time of first vaccination including oral temperature greater than 99.5 °F.
20. The volunteer has a history of abuse of alcohol or drugs within the 12 months before clinical trial screening.
21. The volunteer has occupational or other responsibilities that would prevent completion of participation in the clinical trial in the opinion of the Investigator.
22. The volunteer has a body mass index (BMI) ≥ 35 kg/m2.
23. The volunteer is a member of the team conducting this clinical trial or is in a dependent relationship with the clinical trial investigator.
24. The volunteer has a confirmed positive result on a urine drug screen that tests for common substances of abuse such as amphetamines, barbiturates, benzodiazepines, cocaine, opiates and cannabinoids.
25. The volunteer was seropositive on screening tests for human HIV, Hepatitis C virus or hepatitis B surface antigen.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes